Honz Pharmaceutical (300086.SZ) forecasts a pre-loss, expecting a net loss for the year 2024 of between 154 million and 226 million yuan, turning from profit to loss.
Kangzhi Pharmaceutical (300086.SZ) released its performance forecast for 2024. The company expects its attributable profit for 2024...
Honz Pharmaceutical (300086.SZ) released a performance forecast for the year 2024, the company expects a net loss attributable to the shareholders of the listed company of 154 million to 226 million yuan in 2024, turning from profit to loss; after deducting non-recurring gains and losses, the net loss is expected to be 151 million to 222 million yuan, turning from profit to loss.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
